Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16477 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Niklas Schmedt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim & Eli Lilly, Company Diabetes Alliance.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This study aimed to assess the risk of urinary tract cancers (UTCs), including bladder and renal cancers, in people with type 2 diabetes (T2D) initiating empagliflozin compared with people initiating any dipeptidyl peptidase‐4 inhibitor (DPP‐4i) in the United Kingdom (UK), Sweden, and Finland. Materials and Methods This was a non‐interventional, multi‐country cohort study based on secondary data in Sweden, Finland, and the UK. The study used an active comparator, new user design and included propensity score‐matched adults with T2D initiating empagliflozin or a DPP‐4i between 2014 and 2020 (2021 for the UK). Follow‐up started at the index date (first prescription or dispensation for empagliflozin or a DPP‐4i) and 180 days were considered as the latency period. Incidence rates (IRs) and hazard ratios (HRs) were estimated under an as‐treated approach in each country. HRs were then entered into a random‐effects meta‐analysis.
Results
The main analyses included 151 055 matched people. The mean age for empagliflozin initiators was 57.0–63.2 years across the countries, and most were female (59.6%–67.8%). A meta‐analysis of country‐level HR showed no evidence of an increased risk of UTC (adjusted HR = 0.88, 95% confidence intervals [CIs]: 0.66–1.17), bladder cancer (adjusted HR = 0.91, 95% CI: 0.63–1.33) or renal cancer (adjusted HR = 0.89, 95% CI: 0.57–1.38) for empagliflozin initiators compared with DPP‐4i initiators. Various sensitivity analyses also validated the robustness of the main findings.
Conclusions
No increased risk of UTC, bladder, and renal cancer was observed when empagliflozin initiators were compared with DPP‐4i initiators in this non‐interventional cohort study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
- IQVIA, Tallinn, Estonia.
- IQVIA, Espoo, Finland.
ORCID-Profile: Niklas Schmedt, Ayman Alhamdow, Giorgi Tskhvarashvili, Laura Saarelainen, Xu Qiao, Muriel Lobier, Fabian Hoti
Förderung
- Boehringer Ingelheim & Eli Lilly
- Company Diabetes Alliance
Zitieren
APA
Schmedt, N., Alhamdow, A., Tskhvarashvili, G., Saarelainen, L., Qiao, X., Lobier, M., & Hoti, F. (2025). Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16477
Vancouver
Schmedt N, Alhamdow A, Tskhvarashvili G, Saarelainen L, Qiao X, Lobier M, et al. Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16477
BibTeX
@article{Schmedt2025,
author = {Schmedt, Niklas and Alhamdow, Ayman and Tskhvarashvili, Giorgi and Saarelainen, Laura and Qiao, Xu and Lobier, Muriel and Hoti, Fabian},
title = {Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16477}
}
EUVIMED